Vogl Melanie, Rosenmayr Anna, Bohanes Tomas, Scheed Axel, Brndiar Milos, Stubenberger Elisabeth, Ghanim Bahil
Department of General and Thoracic Surgery, Karl Landsteiner University of Health Sciences, University Hospital Krems, 3500 Krems an der Donau, Austria.
Cancers (Basel). 2021 Feb 6;13(4):658. doi: 10.3390/cancers13040658.
Malignant pleural mesothelioma (MPM) is an aggressive disease with limited treatment response and devastating prognosis. Exposure to asbestos and chronic inflammation are acknowledged as main risk factors. Since immune therapy evolved as a promising novel treatment modality, we want to reevaluate and summarize the role of the inflammatory system in MPM. This review focuses on local tumor associated inflammation on the one hand and systemic inflammatory markers, and their impact on MPM outcome, on the other hand. Identification of new biomarkers helps to select optimal patient tailored therapy, avoid ineffective treatment with its related side effects and consequently improves patient's outcome in this rare disease. Additionally, a better understanding of the tumor promoting and tumor suppressing inflammatory processes, influencing MPM pathogenesis and progression, might also reveal possible new targets for MPM treatment. After reviewing the currently available literature and according to our own research, it is concluded that the suppression of the specific immune system and the activation of its innate counterpart are crucial drivers of MPM aggressiveness translating to poor patient outcome.
恶性胸膜间皮瘤（MPM）是一种侵袭性疾病，治疗反应有限，预后极差。接触石棉和慢性炎症被认为是主要危险因素。由于免疫疗法已发展成为一种有前景的新型治疗方式，我们希望重新评估并总结炎症系统在MPM中的作用。本综述一方面关注局部肿瘤相关炎症，另一方面关注全身炎症标志物及其对MPM预后的影响。识别新的生物标志物有助于选择最佳的个体化患者治疗方案，避免无效治疗及其相关副作用，从而改善这种罕见疾病患者的预后。此外，更好地理解促进肿瘤和抑制肿瘤的炎症过程，这些过程影响MPM的发病机制和进展，也可能揭示MPM治疗的新靶点。在回顾了目前可用的文献并根据我们自己的研究后，得出的结论是，特异性免疫系统的抑制及其固有对应物的激活是MPM侵袭性的关键驱动因素，导致患者预后不良。
